ide-cel in triple-class rrmm: key efficacy and safety data from the karmma trial
Published 3 years ago • 71 plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
2:18
karmma-3 trial updates: ide-cel versus soc in triple-class exposed r/r multiple myeloma
-
5:16
idecabtagene vicleucel in pts with relapsed and refractory multiple myeloma: updated karmma results
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3
-
2:47
karmma-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
5:16
updated karmma results: ide-cel in r/r myeloma
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
6:55
karmma2: efficacy and safety of idecabtagene vicleucel in hrmm pts with early relapse after asct
-
1:35
long-term efficacy and safety of cilta-cel in patients with relapsed/refractory multiple myeloma
-
1:40
karmma-3: phase iii trial of idecabtagene vicleucel in r/r myeloma
-
3:41
characteristics of neurotoxicity associated with ide-cel in pts with rrmm in phase ii karmma
-
5:52
phase ii data from the karmma trial for relapsed/refractory multiple myeloma
-
1:08
safety and efficacy of iberdomide dexamethasone in patients with triple-class refractory myeloma
-
4:16
iberdomide – efficacy and safety in rrmm
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
7:03
updated results of the idecabtagene vicleucel (ide-cel bb2121) crb-401 trial in rr multiple myeloma
-
12:47
efficacy and safety of kdd in rrmm: cross‐study comparison of candor and mmy1001
-
6:12
idecabtagene vicleucel for relapsed and refractory multiple myeloma